Comparative study analyzing survival and safety of bevacizumab/carboplatin/paclitaxel and cisplatin/pemetrexed in chemotherapy-na&iuml;ve patients with advanced non-squamous bronchogenic carcinoma not harboring EGFR mutation | Zendy

Tamer El-Nahas | Zendy; Yasser Abdel Kader | Zendy; Le Chevalier | Zendy; Amr Sakr | Zendy

Open Access

Comparative study analyzing survival and safety of bevacizumab/carboplatin/paclitaxel and cisplatin/pemetrexed in chemotherapy-naïve patients with advanced non-squamous bronchogenic carcinoma not harboring EGFR mutation

Author(s) -

Tamer El-Nahas,

Yasser Abdel Kader,

Le Chevalier,

Amr Sakr

Publication year - 2013

Publication title -

oncotargets and therapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.054

H-Index - 60

ISSN - 1178-6930

DOI - 10.2147/ott.s45906

Subject(s) - pemetrexed , medicine , carboplatin , bevacizumab , oncology , lung cancer , neutropenia , chemotherapy , gastroenterology , cisplatin , paclitaxel

The majority of Egyptian patients with lung cancer present at a late stage of the disease. Bevacizumab/carboplatin/paclitaxel, as well as cisplatin plus pemetrexed, are both standard regimens for advanced non-squamous bronchogenic cancer. This study compares both regimens, in terms of efficacy and toxicity profile, in Egyptian patients.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research